J9176 Elotuzumab (HCPCS) Reimbursement & Policy

HCPCS Level II code J9176 designates elotuzumab dispensed and billed by milligram: “Injection, elotuzumab, 1 mg.” Elotuzumab is an intravenously administered monoclonal antibody used in oncology care; the code allows payers and providers to report biologic drug units precisely for infusion services. Nationally, accurate J-code billing affects drug cost reporting, reimbursement for outpatient infusion services, and inventory management for high-cost oncology therapies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding intent and clinical context, typical sites of administration, and the payer landscape. The publication summarizes common modifiers and billing considerations provided in the input, describes what information is available and what is not, and highlights related operational elements such as per-milligram billing implications for claims and supply management.

This report is written for a national audience and focuses on benchmarks and policy-relevant aspects of billing for high-cost injectable biologics, without state-specific guidance. Data not available in the input.

Billing Code Overview

HCPCS Level II code J9176 describes Injection, elotuzumab, 1 mg. The code represents administration of the monoclonal antibody elotuzumab on a per milligram basis. The service type is injectable biologic therapy. The typical site of service for this medication is outpatient infusion centers or hospital outpatient departments, where patients receive intravenous infusions under clinical supervision.

Data not available in the input.

Clinical Context

A typical patient is an adult with relapsed or refractory multiple myeloma who is a candidate for immunotherapy with elotuzumab. The patient presents to an outpatient infusion center or hospital outpatient department for intravenous administration of J9176 (elotuzumab) dosed per provider orders. Prior to infusion, oncology nursing performs medication verification, allergy check, baseline vital signs, and premedication orders (antipyretic, antihistamine, corticosteroid) as indicated. An indwelling peripheral IV or central venous access device is used depending on venous access and therapy plan. The infusion is administered by an oncology-certified infusion nurse with monitoring for infusion reactions; vital signs are recorded at baseline, periodically during infusion, and post-infusion. The encounter includes documentation of diagnosis(es) justifying therapy, medication lot and NDC verification, infusion start/stop times, any reactions and interventions, and instructions for follow-up oncology visits and laboratory monitoring (CBC, CMP). Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, and occasionally skilled nursing facilities with appropriate oncology infusion capabilities.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard billing	Use when no special modifier applies to the service

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology & Oncology	Medical oncologists and hematologist-oncologists who order/manage elotuzumab therapy
`207RC0000X`	Radiation Oncology	Oncology team member involved in multidisciplinary care (less commonly the drug prescriber)
`363A00000X`	Registered Nurse	Infusion and chemotherapy administration performed by oncology-certified RNs
`363L00000X`	Licensed Practical/Vocational Nurse	Supports infusion under RN or provider supervision
`174400000X`	Hospitalist	Manages inpatient oncology admissions if infusion occurs during hospitalization

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Common indication for elotuzumab in relapsed/refractory multiple myeloma
`C90.02`	Multiple myeloma in relapse	Indicates disease relapse where elotuzumab-based regimens are considered
`C90.01`	Multiple myeloma in remission	Relevant for documentation of maintenance therapy contexts
`D47.Z1`	Monoclonal gammopathy (paraproteinemia)	May be present in plasma cell disorders evaluated for progression to symptomatic myeloma
`Z79.890`	Long term (current) use of other agents and medications	Used to indicate ongoing antineoplastic therapy management when chronic medication therapy is documented

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; initiation of infusion up to 1 hour, single or initial substance/drug	Used when initiating an IV infusion of a chemotherapy or biologic agent such as elotuzumab for up to 1 hour
`96415`	Chemotherapy administration, each additional hour (list separately in addition to code for primary infusion)	Billed for each additional hour of infusion time when elotuzumab infusion exceeds the initial hour
`96417`	Chemotherapy administration, additional sequential infusion, same agent/line (per hour)	Used when multiple-hour continuous infusions require add-on billing (apply per payer rules)
`96365`	Intravenous infusion, initial, up to 1 hour, therapeutic, prophylactic, or diagnostic; other than chemotherapy	Occasionally used for non-chemotherapy biologic infusions in facility settings depending on payer policy
`99070`	Supplies and material (e.g., saline flushes, IV tubing)	Billed for non-covered supplies used in the administration of `J9176` per facility or payer guidelines

OpenPayer

Summary & Overview

HCPCS Level II J9176: Injection, elotuzumab, 1 mg